Pr Jean-Bernard Fourtillan answers questions from Pr Henri Joyeux

A non-profit endowment fund for your health

Professors Jean-Bernard Fourtillan and Henri Joyeux have decided to unite their efforts in order to announce to the general public, at the same time as to healthcare professionals and to researchers, this essential discovery and the medicinal products (single- or dual-compartment patches), in the process of being prepared, which result therefrom.

They created a non-profit endowment fund, the Josefa Fund, to which were given, in their totality, the intellectual property rights to the medicinal product patents resulting from this discovery.

> Read more

This discovery
revolutionises
the understanding
and treatment
of neurological diseases

Available Publications

  • The book - 216 pages.
    All the scientific
    explanations
  • The brochure
    52 illustrated plates with comments
> Discover

Valentonin : key to the discovery

1958-mltA.B. LERNER discovered
Melatonin
Neuroprotective hormone

1961-6mhW.M. Mc ISAAC discovered
6-methoxy-harmalan
Wakefulness hormone

1994-vltJ-B FOURTILLAN discovered
 Valentonin
Sleep hormone

The discovery of
the Sleep-Wake system

makes it possible to understand, for the first time,
how our body functions, alternately in sleep mode
and in waking mode, in 24-hour periods.

Three hormones secreted by the pineal gland
during the night, melatonin (MLT),
6-methoxyharmalan (6-MH) and Valentonin (VLT),
protect our body and guarantee the regulation
of mental and vegetative life.

> Read more

The galenic development of the patches will be fully financed by the Josefa Fund. We are in contact with manufacturers whose task is to deliver to us ready-to-use patches in September 2017.

The European (EP) and international (PCT) patents that protect the therapeutic applications of this discovery have been filed and been given in their entirety to the Josefa Fund.

> Read more

In the fourth quarter of 2017, with the pharmaceutical Laboratories that we will have chosen as partners, we will request a Temporary Use Authorisation (TUA) in order to immediately make these treatments available to patients.

> Read more